18
nanotimes
Companies Facts
azimuth detection accuracy by approximately 40% and helps to reduce calibration time. Low current consumption (200 µA) is also realized.
http://www.alps.com/products/WebObjects/catalog. woa/E/HTML/Switch/Detector/SPVQ4H/
SPVQ4H_list.html
http://www.alps.com
Subscription Agreement (the “SSA”) initially entered into with Canon Investment Holdings Limited (“Canon”) on September 20, 2010 and subsequently amended on February 16, 2011 and May 17, 2011. This Third Amendment to the SSA extends the End Date to, and sets the Closing Date as June 20, 2011, but keeps in place Altairnano‘s ability to pursue other alternatives and to terminate the SSA at any time with no penalty. The SSA calls for Canon to acquire newly issued shares of the Company‘s common stock valued at $57.6 million, resulting in a 51% ownership on a fully diluted basis immediately upon closing. The Company stated in its press release of May 17, 2011 that, as of that point forward, it would be working toward closing with Canon and thoroughly examining alternatives to the Canon deal.
A
Furthermore, Altair Nanotechnologies has been awarded a 3-year lease for its new ALTI-ESS Advan- tage 1.8 MW/ 300 kWh energy storage system. The system will be leased by Energy Storage Holdings, LLC, a unit of a major U.S.-based energy company. The project, to be initially located in New Jersey, will evaluate energy storage technology for large-scale frequency regulation projects, and is expected to be installed in late 2011. This project marks the debut
ltair Nanotechnologies Inc. (NASDAQ: ALTI) has agreed to a third amendment to the Share
Company (NYSE: BMY) resulting from a recently initiated Phase 2 clinical trial of an AMRI compound exclusively licensed to Bristol-Myers Squibb.
A
This is the sixth milestone payment originating from a 2005 agreement in which AMRI licensed to Bristol- Myers Squibb its technology around central nervous system (CNS) triple reuptake transporter inhibitors as potential improved treatments for depression and diseases of the CNS. This payment brings the total milestone and licensing fees earned by AMRI related to the 2005 license agreement to $22.75 million. AMRI has also received $10 million in research col- laboration fees under the agreement. In addition to the compound entering Phase II clinical evaluation, Bristol-Myers Squibb is continuing to evaluate other collaboration compounds for depression and other indications.
Under the collaborative agreement, AMRI is eligible to receive up to $66 million in development and regulatory milestone payments per compound for the first two compounds and payments of up to $22 million per compound on subsequent compounds.
MRI (NASDAQ: AMRI) will receive a $3 million milestone payment from Bristol-Myers Squibb
of the ALTI-ESS Advantage, a 1.8 MW system targe- ted toward frequency regulation and fast-response applications demanding high power.
The ALTI-ESS has more than 2 years of commercial operation providing frequency regulation in the Uni- ted States while demonstrating excellent reliability and uptime.
http://www.altairnano.com
11-05 :: May/June 2011
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80 |
Page 81 |
Page 82 |
Page 83 |
Page 84 |
Page 85 |
Page 86 |
Page 87 |
Page 88 |
Page 89 |
Page 90 |
Page 91 |
Page 92 |
Page 93 |
Page 94 |
Page 95